The treatment of kidney cancer targeted therapy drug Pazopanib
Pazopanib (GW786034) is vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-Kit targeting oral anti-angiogenic agents. Hutson, Texas Baylor Sammons Cancer Center conducted a Phase II clinical trials, drug efficacy and safety of the treatment of metastatic renal cell carcinoma and related biomarkers.
The study included 225 patients with metastatic renal cell carcinoma patients, of which 205 cases (91%) had received prior renal resection, 155 patients (69%) no previous history of systemic therapy. Evaluation of peripheral blood VEGF, sVEGFR-1, sVEGFR-2 levels and tumor tissue VHL gene changes with efficacy.
Pazopanib (800 mg qd) after 12 weeks of treatment, researchers and independent analysts evaluation results, CR 2 cases (0.9%) and three patients (1.3%), PR 74 cases (32.9%) and 75 patients (33.3 %), SD 95 cases (42.2%) and 101 cases (44.9%), Pd 37 cases (16.4%) and 24 patients (10.7%), can not be evaluated efficacy in 17 patients (7.6%) and 22 patients (9.8%), objective and effective in 76 cases (33.8%) and 78 patients (34.7%), PFS 9.9 months and 11.9 months, the onset time of 11.9 weeks and 12.0 weeks, the duration of efficacy of 71 weeks and 68 weeks. 12 weeks of treatment, the blood of sVEGFR-2 levels decreased with a significant effect (P = 0.00002).
The treatment of kidney cancer targeted therapy drug Pazopanib
ReplyDeletePazopanib (GW786034) is vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-Kit targeting oral anti-angiogenic agents. Hutson, Texas Baylor Sammons Cancer Center conducted a Phase II clinical trials, drug efficacy and safety of the treatment of metastatic renal cell carcinoma and related biomarkers.
The study included 225 patients with metastatic renal cell carcinoma patients, of which 205 cases (91%) had received prior renal resection, 155 patients (69%) no previous history of systemic therapy. Evaluation of peripheral blood VEGF, sVEGFR-1, sVEGFR-2 levels and tumor tissue VHL gene changes with efficacy.
Pazopanib (800 mg qd) after 12 weeks of treatment, researchers and independent analysts evaluation results, CR 2 cases (0.9%) and three patients (1.3%), PR 74 cases (32.9%) and 75 patients (33.3 %), SD 95 cases (42.2%) and 101 cases (44.9%), Pd 37 cases (16.4%) and 24 patients (10.7%), can not be evaluated efficacy in 17 patients (7.6%) and 22 patients (9.8%), objective and effective in 76 cases (33.8%) and 78 patients (34.7%), PFS 9.9 months and 11.9 months, the onset time of 11.9 weeks and 12.0 weeks, the duration of efficacy of 71 weeks and 68 weeks. 12 weeks of treatment, the blood of sVEGFR-2 levels decreased with a significant effect (P = 0.00002).
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Tandutinib
KW-2449
Quizartinib
AST 487
Linifanib
Canertinib
Canertinib dihydrochloride
CP-724714 (E-Double bond)
2-Methoxyestradiol
GSK1904529A